VeriChip (CHIP) Partners with Diabetes Research Institute on Glucose-Sensing RFID Microchip
VeriChip Corporation (NASDAQ: CHIP) announced today that it has entered into a strategic partnership with the Diabetes Research Institute to combine efforts on the further development of the glucose-sensing radio frequency identification (RFID) microchip in conjunction with VeriChip's development partner, RECEPTORS LLC.
VeriChip and DRI also intend to create a prospective, randomized, comparative clinical study that will seek to address the lack of appropriate, concise, and up-to-date patient health information available to both practitioners caring for diabetic patients and the patients themselves through the utilization of VeriChip's interoperable personal health record, Health Link, and an electronic medical record system.
VeriChip previously announced in November 2008 that RECEPTORS completed Phase I of the development of the glucose-sensing RFID microchip, which demonstrated the proof-of-concept foundation of the glucose-sensing system. The companies expect Phase II will demonstrate a glucose concentration response in the presence of blood and interstitial fluid matrix components.
Create E-mail AlertRelated Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
